top of page
Commitment to Neurotherapeutics

Aquilus Pharmaceuticals is dedicated to developing a first-in-class medication for neurodegenerative diseases, with a primary focus on Amyotrophic Lateral Sclerosis (ALS). Our mission is to make a meaningful impact on patients' lives by advancing therapeutics in this challenging field

ABOUT

Our 
Story

Calm Sea

Aquilus Pharmaceuticals is a Pre-series A biotech that has been funded via the ALS Association, NIH, and Department of Defense grants in developing a new therapeutic (AQU - 118) to treat Amyotrophic Lateral Sclerosis (ALS)

Under Water

What is ALS?

Under Water

Amyotrophic Lateral Sclerosis (ALS) is a rare multisystem multifactorial disease with peripheral contributions to immune-mediated loss of upper and lower motor neurons causing paralysis and muscular atrophy impairing the ability to speak, eat, move and eventually breathe. Age at diagnosis ranges from 40-70 years but can occur as young as 20-30 years old. While most cases are sporadic, 5-10% are familial. 

Life expectancy is 2-5 years after diagnosis
 

  1. ALS association.

  2. Maksimovic K. Evidence of Metabolic Dysfunction in ALS. Patient and Animal Models. Biomolecules. May 2023

  3. Mentis AFA. ALS and the Endocrine System: Are There Any Further Ties to Be Explored? Aging Brain. 11/8/2021

  4. Zhang S. Genome-wide Identification of the Genetic Basis of ALS. Neuron. Volume 110. Issue 6, 3/16/2022. 

PROJECTS

LATEST
RESEARCH INITIATIVES

Matrix Metalloproteinases (MMPs)
MMP's are a family of around 24 zinc-dependent endopeptidases. As a family, MMPs can cleave virtually any component of the extracellular matrix, and thereby facilitate cell migration and affect cellular signaling that regulates cell proliferation, differentiation, and cell death. In addition to cleaving the structural components of the extracellular matrix, MMPs are involved in the processing & signaling of growth factors and their receptors, cytokines, chemokines, adhesion molecules, and a variety of other enzymes such as caspases. A growing body of evidence has linked MMP-9 and MMP-2 with the severity and rate of progression of ALS. Currently, there are no FDA approved MMP inhibitors.
Laboratory
Under Water

Aquilus' MMP inhibitor AQU-118

Under Water

Aquilus has developed a small molecule called AQU-118 that is a safe, orally bioavailable semi-selective inhibitor of MMP-9 and MMP-2. It has been found to significantly reduce nerve damage in several different rodent animal models of neuropathic pain and nerve injury as well as mitigate weight loss and reduced grip strength in the TDP-43 over-expressed  mouse model of ALS.


*Henry, M.A. Effect of a novel, orally active matrix metalloproteinease-2 and-9 inhibitor in spinal and trigeminal rat models of neuropathic pain. J. Oral Fac. Pain Headache 2015, 29, 286–296. 
*Kwan, M.Y. Biomarker analysis of orally dosed, dual active, matrix metalloproteinase (MMP)-2 and MMP-9 inhibitor, AQU-118, in the spinal nerve ligation (SNL) rat model of neuropathic pain. Int. J. Mol. Sci. 2019, 20, 811. 

OUR FOCUS

RESEARCH & DEVELOPMENT

Aquilus is committed to driving progress in neurodegenerative disease treatment through cutting-edge research and development efforts.

CLINICAL TRIALS

Aquilus has completed all necessary IND enabling studies for AQU-118 and currently on track towards a phase I trial in the first quarter of 2025. Plans for the recruitment for the phase II trial to begin in the fourth quarter of 2025

CONNECTING WITH THE COMMUNITY

We partner with people  who are directly impacted by neurodegenerative disease to give us guidance from the patient and caregiver perspective

SERVICES
THE TEAM
bubbles under water_edited.jpg

Senior Leadership

Our core team of experts is driven by a shared passion for making a difference in the lives of patients facing neurodegenerative diseases.

Irving pic.jpg
Irving Sucholeiki, Ph.D

 President & Chief Executive Officer

Darrell J. Nix, Ph.D.
 

Vice President, R & D

Roy Sucholeiki, M.D.

CMO & Vice President, Clinical Development

Dr. Sucholeiki leads our research initiatives, leveraging his 25 + years of experience in drug discovery and development to drive our scientific endeavors forward.

With over 20 years of industry experience as a pharmacologist, Dr.  Nix guides the regulatory requirements for Aquilus' goal of FDA approval

With over 25 years of clinical experience and academic research, Dr. Sucholeiki spearheads Aquilus' clinical trials path

OUR PARTNERS

ALS Assoc logo.jpg
dod logo.jpg
NIH logo.jpg
ALS patient support network.jpg
EverythingALS.jpg
CLIENTS

OUR COLLABORATORS AND ADVISORS

Robert Bowser, Ph.D, Chairman, Dept of Neurobiology, Barrow Neurological Institute​

Merit Cudkowicz, M.D., MSc., Professor, Harvard Medical School & Director, Sean M. Healey & AMG Center for ALS​

Sabrina Paganoni, M.D., Associate Professor, Harvard Medical School & Co Director, MGH Neurological Clinical Research Institute​

Daniela Zarnescu, Ph.D, Professor of Molecular & Cellular Biology, University of Arizona​

Professor Rita Sattler, MSc., Ph.D., Associate Professor, Barrow Neurological Research Institute
   

CLIENTS
bubbles under water_edited.jpg

NEWS

  • 2024 Human Research Ethics Committee Approval to Begin Phase 1 Single and Multiple Ascending Dose Clinical Trial

  • 2023 The Hoffman ALS Clincal Trial Grant Award ($1,000,000)
  • 2021 Department of Defense ALS Research Program Therapeutic Development  Grant Award ($ 1,000,000)
  • 2021 Lawrence and Isabel Barnett Drug Development ALS Association Grant Award ($ 500,000)
  • 2019 National Institutes of Health Small Business Innovation Research Grant Award ($ 457,639)  
CONTACT

GET IN TOUCH

Thanks for submitting! We will respond ASAP

©2024 Copyright Aquilus Pharmaceuticals, Inc. All rights reserved.
bottom of page